呼吸系统肿瘤.doc

·呼吸系统肿瘤· BIII001 Genetic Analysis of the Separate Morphologic Components in Combined Small Cell Lung Cancer Hong-Yang Lu1,3 Bo Chen2 Ju-Fen Cai3 Xiao-Jia Wang3 Lei Lei3 Cai-Jin Lou3 Jing Qin3 Wei-Wu Ye3 Zhi-Qiang Ling1 Wei-Min Mao1 1310022 Hangzhou ZhejiangZhejiang Key Laboratory of Diagnosis Treatment Technology on Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, 2310022 Hangzhou Departments of Pathology Zhejiang Cancer Hospital, 3310022 Hangzhou Departments of Medical Oncology, Zhejiang Cancer Hospital, Purpose: Combined small cell lung cancer (CSCLC) is currently considered a subset of SCLC and have been reported to account for less than 1-3.2% of all SCLCs. Accurate understanding of CSCLCs is of great importance because treatment strategies are significantly different for NSCLC and SCLC. To address molecular features of different components in CSCLC we analyzed mutation status in CSCLC tumor samples in EGFR signal pathway. Materials and Method: Seven CSCLC samples were included in direct sequencing for mutation analysis of EGFR, KRAS, PIK3CA, BRAF, and PTEN. Results: Mutations were detected in 4 of 7 (57.1%) CSCLC patients. EGFR Exon 18 mutations were identified in two patients among whom the mutation was identified in both adenocarcinoma component and SCLC combined adenocarcinoma component of one patient. The similar situation also happened in another one with PTEN C511T mutations both conventional SCLC component and SCLC combined adenocarcinoma component. Both KRAS and PIK3CA were detected in one SCLC combined adenocarcinoma patient and no mutation in BRAF was identified. Conclusion: Our result is consistent with previous work that the individual components of CSCLC are closely related, despite their distinct morphologic appearances. BIII002 Identification of lymphovascular invasion as a potential prognosticator for patients with surgery-treated non-small cell lung cancer: Data from MD Anderson Cancer Center Jun Wang